Replies to post #744368 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

But big megaphones won’t matter if they don’t fill in the blanks. They must name product collaborators, products and terms of licensing (as licensors and as licensees), name parties in contracts they state they’ve already signed (and any they are about to sign), IND status, Flaskworks progress, Direct progress, any and all planned or consummated nondilutive funding, status of NICE application and if CDF funding attempted and what transpired. Either these guys have been on crack or they’ve been cracking the whip behind the scenes. We need massive transparency upon any approval. The patience and understanding about the details trickle due to regulatory review will, imo, end upon any approval.

Les gave away GM’ s electric car and musk finally found it.

Les essentially gave away a widow’s property to Trump.

This would be strike three for Les*, if he intends to choke on filling in the blanks upon/surrounding DCVax-l’s (likely) approval.

[CrashOverride]

Management are seeking redress from market makers which are illegally spoofing our shares all day every day.

I deposited more cash and will buy again on 1/27/2025.

If shareholders want to see the price go up then they should do the same.

[RobotDroid]

This worthless nonmanagement team has shown they don't care about SH a tiny bit. Worst I have ever seen, zero communication, zero pr's, zero accountability. Grifters to the end all led by the worlds worst ceo. The lawsuits will be legendary.

[learningcurve2020]

It’d all need to happen a lot earlier than that, like I said earlier.

>>must be strong and sustained and it must begin the moment MHRA news hits.

[Investor082]

Why would they hide if they have anything meaningful to share? That simply doesn’t make any sense. The reality is they don’t have any earth shattering news to share. They know that Oncovir and other such in licensing deals/partnerships will have no impact on the share price. There will be nothing meaningful to share on Flaskworks and reimbursement either, both of which won’t come online until 2026 at the earliest.

The only news that will help move the share price in a massive way and importantly keep it sustained will be a PR from big pharma saying they are partnering with NWBO and injecting capital (whether it’s dilutive or non dilutive doesn’t matter). Unfortunately, this is not happening in 2025 either. Instead, NWBO will announce a collaboration trial in isolation, announce a partnership with Oncovir, and the stock will be slammed given the lack of support from big pharma, immediate cash needs (hence ton of dilution), and no buyout/exit potential in the future!

Just wait and watch to see this play out! Or don’t give LP the opportunity to fool you again and sell at the UK approval spike before you get sucked into the waiting game again like a bag holder.